Vantage Wealth Has $14.72 Million Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Vantage Wealth raised its position in Agilent Technologies, Inc. (NYSE:A) by 2.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 109,590 shares of the medical research company’s stock after buying an additional 2,980 shares during the quarter. Agilent Technologies accounts for 3.2% of Vantage Wealth’s holdings, making the stock its 23rd biggest holding. Vantage Wealth’s holdings in Agilent Technologies were worth $14,722,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. McAdam LLC lifted its position in shares of Agilent Technologies by 3.1% during the 3rd quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock valued at $376,000 after acquiring an additional 77 shares during the period. Brown Brothers Harriman & Co. lifted its position in shares of Agilent Technologies by 13.5% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock valued at $96,000 after acquiring an additional 77 shares during the period. Global Retirement Partners LLC lifted its position in shares of Agilent Technologies by 3.2% during the 3rd quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock valued at $382,000 after acquiring an additional 79 shares during the period. Rovin Capital UT ADV lifted its position in shares of Agilent Technologies by 1.6% during the 3rd quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock valued at $750,000 after acquiring an additional 81 shares during the period. Finally, Marshall Financial Group LLC lifted its position in shares of Agilent Technologies by 1.0% during the 3rd quarter. Marshall Financial Group LLC now owns 8,243 shares of the medical research company’s stock valued at $1,224,000 after acquiring an additional 82 shares during the period.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares of the company’s stock, valued at $5,947,800. This trade represents a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Wall Street Analysts Forecast Growth

A has been the subject of a number of recent analyst reports. Bank of America cut their target price on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. StockNews.com upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Evercore ISI upped their price objective on Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Sanford C. Bernstein dropped their price objective on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research report on Tuesday, November 26th. Finally, JPMorgan Chase & Co. dropped their price objective on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Agilent Technologies currently has an average rating of “Hold” and an average price target of $143.62.

Agilent Technologies Trading Down 0.8 %

Shares of A stock opened at $151.24 on Friday. The stock has a market cap of $43.19 billion, a price-to-earnings ratio of 34.22, a PEG ratio of 4.12 and a beta of 1.06. The stock has a 50-day moving average of $138.43 and a 200-day moving average of $138.06. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57. Agilent Technologies, Inc. has a 1-year low of $124.16 and a 1-year high of $155.35.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.41 by $0.05. The company had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The business’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.38 earnings per share. On average, equities research analysts forecast that Agilent Technologies, Inc. will post 5.56 earnings per share for the current year.

Agilent Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 22nd. Investors of record on Tuesday, December 31st were paid a dividend of $0.248 per share. The ex-dividend date of this dividend was Tuesday, December 31st. This represents a $0.99 annualized dividend and a yield of 0.66%. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.24. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.40%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.